| Item |
Information |
|
Drug Groups
|
approved; withdrawn |
|
Description
|
Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. |
| Indication |
For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery. |
| Pharmacology |
Ardeparin, an anticoagulant, is a fractionated heparin. It acts at multiple sites in the normal coagulation system to inhibit reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. |
| Toxicity |
Symptoms of overdose may include excessive bleeding and bruising. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Liver and the reticulo-endothelial system are the sites of biotransformation. |
| Absorption |
Well absorbed following subcutaneous administration, with a mean bioavailability of 92% (based on anti-factor Xa activity). |
| Half Life |
Elimination half-life for anti-factor Xa activity averages 3.3 hours following a single intravenous dose, while elimination half-life for anti-factor IIa activity averages 1.2 hours following a single intravenous dose. |
| External Links |
|